BURN WOUND INFECTIONS TREATMENT & MANAGEMENT IN PAKISTAN

Aim: To analyze the treatment options for burn infections and determine the antibiotic sensitivity and resistance pattern and antibiotic consumption in defined daily dose. Place and Duration: In the Department of Burn and plastic surgery, Mayo Hospital Lahore for one year duration from March 2019 to March 2020. Materials and methods: Patients with burns admitted between March 2018 and March 2019 were selected for the study. Patient demographics, total burn area (TBSA), burns, treatment table, days of hospitalization, and antibiotic susceptibility / resistance profile were recorded. The cumulative susceptibility / resistance pattern (in percent) of microorganisms isolated against various antibiotics was calculated based on the culture sensitivity reports. The total use of the antibiotic in burn patients was calculated as DDD / 100 BD using the antibiotic consumption calculator - WHO ABC Calc version 3.1. The patient additionally were planned for daily debridement and papaya dressing. Results: Thermal burns (81.8%) were the main cause of burns in 159 patients. The most commonly prescribed antibiotic was cefoperazone-sulbactam (54.7%), followed by amoxicillin-clavulanic acid (34%). In total, 82 bacterial isolates were obtained, among which the most common organism was Pseudomonas aeruginosa (31.6%). P. aeruginosa was sensitive to rifampin and erythromycin but was resistant to clindamycin. 90% of the infections in patients were managed conservatively with appropriate antibiotics after culture sensitivity and 10 percent needed debridement and papaya dressing for wounds. Conclusion: Appropriate antibiograms will facilitate the conceptualization and development of drug policy to improve burn treatment results. Appropriate preventive and therapeutic measures should be taken to provide social education and quality medical care to reduce the incidence of burn patients and improve survival outcomes. Keywords: Sensitivity to antibiotics, burns, specific daily dose in burns, assessment of drug us